Recursion Pharmaceuticals Receives JPMorgan Upgrade Following Positive Clinical Trial Results
JPMorgan upgraded Recursion Pharmaceuticals to Overweight with a higher price target after promising clinical data for its drug REC-4881 in treating Familial Adenomatous Polyposis.